Searching for a cagrilintide retatrutide metabolic outcomes study can lead to a misleading impression: that these two investigational compounds have been tested together or directly compared. The supplied research references do not identify such a study. Instead, they describe separate development programmes from rival pharmaceutical companies, with different treatments, trial designs and reporting timelines.

Cagrilintide belongs to Novo Nordisk’s research programme, while retatrutide is being developed by Eli Lilly. The relevant studies are REDEFINE 1, which evaluated CagriSema and its individual components, and TRIUMPH-1, which evaluated retatrutide. Understanding that distinction is essential before interpreting their reported weight-loss results or drawing conclusions about metabolic outcomes.

What the Cagrilintide and Retatrutide Research Actually Shows

No combined cagrilintide-retatrutide trial or head-to-head comparison appears in the company releases or FDA communications identified in the supplied reference material. That means there is no supported result for the two compounds used together, and no direct trial evidence establishing which performs better.

The real research concerns separate investigational treatments:

• Cagrilintide: a long-acting amylin analogue peptide developed by Novo Nordisk.
• CagriSema: Novo Nordisk’s investigational combination of cagrilintide and semaglutide.
• Retatrutide: Eli Lilly’s investigational triple-agonist treatment, evaluated separately from cagrilintide.

The names are easy to confuse because they appear in discussions about obesity research and metabolic health. However, shared research interests do not make separate clinical programmes a combined study.

Cagrilintide Is Not the Same Treatment as CagriSema

One of the most important distinctions is between cagrilintide alone and CagriSema. CagriSema combines cagrilintide with semaglutide. It does not contain retatrutide.

This matters because a result reported for CagriSema cannot automatically be attributed to cagrilintide alone. A combination treatment is evaluated as its own intervention, and its findings must be described accordingly.

Similarly, evidence about CagriSema does not establish what would happen if cagrilintide were paired with a different investigational compound. The supplied sources provide no evidence for a cagrilintide-retatrutide combination.

REDEFINE 1: The Relevant Novo Nordisk Study

In its 20 December 2024 announcement, Novo Nordisk reported results from REDEFINE 1. The study included 3,417 participants and evaluated outcomes over 68 weeks.

The reported findings included:

• CagriSema: 22.7% weight reduction.
• Placebo: 2.3% weight reduction.
• Cagrilintide alone: 11.8% weight reduction.

These figures belong to the REDEFINE 1 research programme. They are not results from a comparison with retatrutide, nor do they describe the effects of combining cagrilintide and retatrutide.

Why the Treatment Label Matters

A headline that presents the CagriSema figure as a cagrilintide-only result leaves out a crucial detail: semaglutide was part of the combination. Accurate reporting should identify the treatment associated with each percentage rather than grouping all results under the name cagrilintide.

Likewise, the cagrilintide-alone finding should remain attached to its own study arm. Keeping these labels clear prevents readers from confusing a single investigational compound with a combination treatment.

TRIUMPH-1: The Separate Retatrutide Study

Eli Lilly reported TRIUMPH-1 results on 21 May 2026 in its retatrutide research announcement. This study included 2,339 participants and evaluated outcomes over 80 weeks.

Across the three retatrutide treatment groups identified in the supplied reference, reported weight reductions were 19.0%, 25.9% and 28.3%, compared with 2.2% for placebo.

These are findings from a separate trial. TRIUMPH-1 did not establish the effects of retatrutide combined with cagrilintide, and the supplied material does not identify a cagrilintide comparison arm.

What These Results Can Establish

The announcement provides evidence about retatrutide within the conditions of TRIUMPH-1. It does not provide a direct answer to whether retatrutide produces better outcomes than cagrilintide or CagriSema.

That distinction is not merely technical. A trial’s participants, duration, treatment groups and analysis methods shape how its results should be interpreted. Findings are most meaningful when kept within that context.

Why the Weight-Loss Percentages Are Not a Head-to-Head Comparison

It may be tempting to place the REDEFINE 1 and TRIUMPH-1 percentages side by side and declare a winner. Doing so would turn separate trial results into an unsupported comparative claim.

The supplied references already show important differences. REDEFINE 1 ran for 68 weeks, while TRIUMPH-1 ran for 80 weeks. The studies also enrolled different numbers of participants and evaluated different treatments.

More broadly, interpreting results across separate trials requires attention to factors such as:

• Participant characteristics and eligibility criteria.
• The duration of treatment and follow-up.
• How treatment discontinuation and missing data were handled.
• The statistical approach used to calculate the reported results.
• The outcomes selected for evaluation.

A direct comparative trial would be needed to support a clear head-to-head conclusion. The supplied references do not identify one.

Weight Loss Is Not the Whole Metabolic Outcomes Picture

The phrase metabolic outcomes is broader than body-weight change. Depending on a study’s design, it can encompass measures related to glucose regulation, blood lipids, blood pressure or other aspects of metabolic health.

However, the specific figures supplied here concern weight reduction. They should not be used to invent conclusions about cardiovascular events, diabetes prevention, liver outcomes or other endpoints not documented in the reference material.

Weight-loss findings also do not establish that two investigational compounds are interchangeable. Nor do they show that combining them would be effective or safe. Each proposed treatment and outcome requires its own supporting evidence.

Approval Status: Research Results Are Not Authorisation

Promising clinical results and regulatory approval are different milestones. A company announcement does not itself authorise a treatment for clinical use.

According to the supplied reference material, Novo Nordisk filed a New Drug Application for CagriSema on 18 December 2025, with a US decision expected in the fourth quarter of 2026. CagriSema is described as not approved. The filing concerns CagriSema, not a cagrilintide-retatrutide combination.

Retatrutide also remains investigational, with a filing planned for the first quarter of 2027. A planned submission is not an approval, and an expected decision date does not guarantee a favourable decision.

How to Check Claims About a Cagrilintide-Retatrutide Study

When an article, product page or social media post claims that these compounds have been studied together, look for a clearly identified clinical trial and a primary source.

• Check the treatment names: CagriSema means cagrilintide plus semaglutide, not retatrutide.
• Check the study name: REDEFINE 1 and TRIUMPH-1 are separate trials.
• Check the comparison: Results from different studies are not head-to-head evidence.
• Check the endpoint: Weight reduction should not be relabelled as proof of every metabolic benefit.
• Check the regulatory status: Investigational treatments should be identified plainly as such.

The Bottom Line

The real research is about CagriSema and cagrilintide in REDEFINE 1, and retatrutide in TRIUMPH-1. The supplied sources do not identify a combined or head-to-head cagrilintide-retatrutide study.

Accurate interpretation keeps each result attached to its treatment, trial and endpoint. It does not add percentages together, infer combination benefits or treat separate studies as a direct comparison. This article describes investigational research; it does not provide dosing instructions, recommend combining compounds or offer medical advice.